Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles
CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufacture the NK cell product for Cytosen’s upcoming Phase II trial evaluating company’s CSTD002-NK in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), expected to begin the first half of 2019. KBI will also manufacture CytoSen’s proprietary nanoparticles used in the exp...
